The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

REACH2 study: What is the risk of losing response to ruxolitinib over time?

During the Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub spoke to Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR. We asked, What is the risk of losing response to ruxolitinib over time?

REACH2 study: What is the risk of losing response to ruxolitinib over time?

In this video, Mohty reports on a follow-up from the phase III REACH2 trial, comparing the use of ruxolitinib as salvage treatment versus best available therapy for patients with steroid-refractory acute GvHD.

 

Share: